Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 718.98

+2.1%

1:05 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/26/2018 1:11:40 PM
	of 3559

RE: Dupi Many analysts are predicting (speculate) that next growth driver in Dupi sale would be asthma adult/adolescent indication. How they can explain that there was NO SINGLE pulmonologist that write Rx off-label Dupi for this indication, especially when everyone is speaking about large portion of pts with AD/asthma co-morbidity status? For sure some of them are severe on asthma and moderate on AD! Are payers that much restricted in Dupi use, or analysts are BS as usually? Based on current trend, my speculated 1Q US-Dupi sale # are toward $180-190 M, and about $1B for full year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next